-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Volition’s collaboration with Professor Lea Payen and Hospices Civils de Lyon.
- Share
- Tweet
- Share on Facebook
- Share
Professor Lea payen is an expert in molecular biology and toxicology and is leading the collaboration between Hospital of Lyon and Volition, to validate Volition’s biomarker test.
This collaboration is a part of our strategy to attain certification under the In Vitro Diagnostic Regulation (IVDR), while also engaging industry leaders in the development and adoption of our transformative Nucleosomics™ technology in a range of exemplifications of our assays.
Working with centres of excellence, such as the Hospital of Lyon, and providing leading clinicians and researchers with exclusive, early access to our Nu.Q® product range, is an enormous step forward for Volition and a critical phase in our path to commercialization. Professor Payen’s team has been working on validating our Nucleosomics™ technology, focusing on its efficacy in lung cancer and NETosis.
Watch our video to learn more:
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields